Respiratory Disease in Portugal



Introduction

The IRC, a coalition of respiratory clinicians, patients and industry partners, aims to transform post-pandemic respiratory care and reduce mortality by a third globally by 2030 - in line with the UN Sustainable Development Goals.

The IRC is calling on governments and policy makers to establish funded national strategies, which include prevention, new models of care, ambitious measurable targets, and accountable leadership to improve lung health by focusing on:

Better...

- 1. Prevention of respiratory diseases
- Access to the right treatment at the right time
- 3. Action on reducing inequalities
- Prioritisation of research, data and insight to improve care

As outlined in the recently adopted Plano Nacional de Saúde 2021-2030, the Portuguese government has been working on health system reforms by setting new objectives to improve national well-being. A key focus of these efforts is reducing premature mortality, particularly by addressing respiratory diseases through the National Programme for Respiratory Diseases and lung cancer through the National Programme for Oncology.

The IRC welcomes the work on this initiative and is also committed to collaborating with all relevant stakeholders in promoting lung health across Portugal by developing national strategies.

Societal economic cost by disease:



Asthma €926.9 million



COPD **€2.0 billion**



Lung Cancer **€2.2 billion**



respiratory tract infections

€1.6 billion



Mesothelioma €27.2 million



Tuberculosis €90.9 million




Interstitial lung disease €262.5 million



COVID-19 **€4.5 billion**



Pulmonary arterial hypertension **€21.3 million**



29.7 thousand deaths from respiratory diseases



554.4 thousand healthy life years lost to respiratory diseases





This initiative is made possible with the contributions of the partner organisations who all support the IRC's goals: Expertise and time were provided by the European Respiratory Society, European Lung Foundation and Global Allergy and Airways Patient Platform; funding, expertise and time were contributed by AstraZeneca, Chiesi Group, GSK, Sanofi and Regeneron; additional funding was provided by Boehringer Ingelheim.